MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.535
-0.270
-7.10%
After Hours: 3.540 +0.005 +0.14% 19:59 01/24 EST
OPEN
3.690
PREV CLOSE
3.805
HIGH
3.695
LOW
3.150
VOLUME
16.75M
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
3.150
MARKET CAP
1.27B
P/E (TTM)
-2.8883
1D
5D
1M
3M
1Y
5Y
BRIEF-Sorrento Therapeutics Receives Purchase Order For 10 Million Covistix Tests
reuters.com · 10h ago
Sorrento receives purchase order for 10M Covistix tests from its subsidiary for delivery in Mexico
Sorrento Therapeutics (NASDAQ:SRNE) and Sorrento Mexico announce that Mexican regulatory agency, COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) has given emergency use authorization (EUA) approval to Sorrento Mexico to import, mar...
Seekingalpha · 11h ago
Sorrento Receives Purchase Order for 10 Million Covistix Tests From Its Subsidiary Sorrento Mexico for February Delivery in Mexico
As COVID-19 cases spike in Mexico, Sorrento Therapeutics Mexico (“Sorrento Mexico”) won the first tender offer in 2022 by the Mexico City Government for COVISTIX tests, which were delivered in the same week of the tender purchase.Sorrento Mexico has receiv...
GlobeNewswire · 11h ago
Sorrento Therapeutics' Mexican Unit Orders 10 Million COVID-19 Rapid Antigen Tests
MT Newswires · 14h ago
Sorrento Therapeutics Reports Its Covishield 'Potently' Neutralizes Omicron, Omicron Variants Of SARS-CoV-2
  COVISHIELD (STI-9167) neutralizing antibody (nAb) was discovered by scientists from the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) and further optimized and engineered by Sorrento
Benzinga · 3d ago
Sorrento Therapeutics Announces Covishield (Sti-9167), a Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346k) Variants of Sars-Cov-2
COVISHIELD (STI-9167) neutralizing antibody (nAb) was discovered by scientists from the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) and further optimized and engineered by Sorrento scientists.A preprint manuscript is published online at b...
GlobeNewswire · 3d ago
Donald L. Hagan, LLC Buys Day Hagan/Ned Davis Research Smart Sector Fixed In, SPDR Portfolio ...
Sarasota, FL, based Investment company Donald L. Hagan, LLC (Current Portfolio) buys Day Hagan/Ned Davis Research Smart Sector Fixed In, SPDR Portfolio Mortgage Backed Bond ETF, SPDR Portfolio Short Term Treasury ETF, SPDR Portfolio Long Term Treasury ETF,...
GuruFocus.com · 4d ago
Sorrento says COVID-19 antibody neutralized Omicron in lab studies
Sorrento Therapeutics (NASDAQ:SRNE) cited in vivo studies to suggest that the company’s experimental antibody (nAb) STI-9167 demonstrated strong protection against the Omicron variant of COVID-19. The experimental therapy named COVISHIELD
Seekingalpha · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRNE. Analyze the recent business situations of Sorrento Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SRNE stock price target is 26.33 with a high estimate of 35.00 and a low estimate of 18.00.
High35.00
Average26.33
Low18.00
Current 3.535
EPS
Actual
Estimate
0.221.011.802.60
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 282
Institutional Holdings: 91.61M
% Owned: 25.56%
Shares Outstanding: 358.41M
TypeInstitutionsShares
Increased
68
10.47M
New
29
628.13K
Decreased
51
1.86M
Sold Out
18
964.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Henry Ji
Lead Director/Independent Director
Dorman Followwill
Director
Kim Janda
Director
Jaisim Shah
Independent Director
David Lemus
Independent Director
Robin Smith
Independent Director
Yue Wu
No Data
About SRNE
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its proprietary G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company's multimodal, multipronged approach to fighting cancer is made possible by immuno-oncology platforms, including key assets such as fully human antibodies, clinical-stage immuno-cellular therapies, antibody-drug conjugates, and clinical-stage oncolytic virus. It is also developing potential antiviral therapies and vaccines against coronaviruses, which includes COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC, and COVI-DROPS.

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNE stock methods without spending real money on the virtual paper trading platform.